View details of this raise on Seedstage

Henderson, NV

Developing a regenerative solution for osteoporosis to improve bone health.

• Patented Technology: OsNovum has developed a patented bone-regenerating technology aimed at the osteoporosis market.
• FDA Clearance: The technology is FDA-cleared for maxillofacial bone and is being adapted for full skeletal applications.
• Proven Success: Thousands of patients have been successfully treated with OsNovum’s regenerative bone solutions.
• Strategic Expansion: Plans to launch in key U.S. markets and expand internationally to meet demand.
• Experienced Team: The team includes industry leaders with decades of experience in biotechnology and regulatory compliance.

OsNovum is advancing a novel regenerative solution for osteoporosis and osteopenia, conditions that significantly impact mobility and quality of life for millions globally. The company’s technology focuses on regenerating poorly mineralized bone into dense, healthy bone by targeting the patient’s own bone-growing cells, known as osteoblasts. This approach aims to stimulate natural regeneration without the systemic side effects associated with current treatments. OsNovum’s technology has already been FDA-cleared for maxillofacial applications and is now being adapted for broader skeletal use.

The company is strategically positioned to capture a share of the projected $25.3 billion osteoporosis market by 2025. With a team of seasoned industry leaders and regulatory experts, OsNovum is on track to submit a De Novo application, a critical step towards market entry. The company plans to establish specialized clinics to provide access to its innovative treatments. OsNovum’s commitment to transforming bone health is supported by its proven technology and a clear regulatory path, aiming to deliver groundbreaking solutions to patients in need.

Company Info

OsNovum develops regenerative solutions for osteoporosis, focusing on natural bone regeneration through innovative technology.

OsNovum is pioneering a breakthrough solution for osteoporosis and osteopenia, conditions that significantly impact mobility and quality of life for millions worldwide. The company focuses on transforming bone health through innovative regenerative technology, aiming to provide a more effective alternative to current treatments that often come with severe side effects. By targeting the patient’s own bone-growing cells, OsNovum’s patented molecule stimulates natural bone regeneration without systemic risks.

Building on decades of research, OsNovum’s technology has already been FDA-cleared for maxillofacial applications and is now being adapted for skeletal use. The company plans to establish specialized clinics to provide access to these advanced treatments. With a strategic path to market entry and a team of seasoned industry leaders, OsNovum is well-positioned to capture a significant share of the global osteoporosis market, which is projected to reach $25.3 billion by 2025.